Yonghoon Choi1, Nayoung Kim2,3, Chang Yong Yun1, Yoon Jin Choi1, Hyuk Yoon1, Cheol Min Shin1, Young Soo Park1, Sang-Hoon Ahn4, Do Joong Park4,5, Hye Seung Lee6,7, Ji-Won Kim8, Jin Won Kim8, Keun-Wook Lee8,9, Won Chang10, Ji Hoon Park10, Yoon Jin Lee10, Kyoung Ho Lee10,11, Young Hoon Kim10,11, Dong Ho Lee1,9, Hyung-Ho Kim4,5. 1. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea. 2. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea. nakim49@snu.ac.kr. 3. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea. nakim49@snu.ac.kr. 4. Department of Surgery, Seoul National University Bundang Hospital, Seongnam, Korea. 5. Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea. 6. Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea. 7. Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea. 8. Department of Oncology, Seoul National University Bundang Hospital, Seongnam, Korea. 9. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea. 10. Department of Radiology, Seoul National University Bundang Hospital, Seongnam, Korea. 11. Department of Radiology, Seoul National University College of Medicine, Seoul, South Korea.
Abstract
OBJECTIVE: Helicobacter pylori (HP) is known to play an important role in the development of gastric cancer (GC). The aim of this study was to analyze the effect of HP eradication on the survival rate and cancer recurrence in patients who underwent subtotal gastrectomy for GC. DESIGN: Totally 1,031 patients diagnosed with gastric adenocarcinoma who received surgical treatment at the Seoul National University Bundang Hospital from 2003 to 2017 and positive for HP infection were analyzed. The overall and GC-related survival according to HP eradication were compared; risk factors for GC-specific death and cancer recurrence were analyzed, and propensity score matching (PSM) was performed. RESULTS: Statistically significant benefits of overall and GC-specific survival were observed in the eradicated group compared to the non-eradicated group (P < 0.001), and these benefits were maintained after PSM (P < 0.001) in both of early and advance stage. In Cox proportional hazards multivariate analyses, cancer stage (stage II, adjusted hazard ratio [aHR] = 9.33, P < 0.001; stage III or IV, aHR = 26.17, P < 0.001), and HP positivity (aHR = 3.41, P = 0.001) were independent risk factors for GC-specific death; cancer stage (cancer stage II, aHR = 7.08, P < 0.001; cancer stage III or IV, aHR = 19.64, P < 0.001) and HP positivity (aHR = 2.70; P = 0.005) were independent risk factors for cancer recurrence. CONCLUSION: Our results suggest that HP needed to be conducted more intensively in patients who are surgically treated for GC, regardless of cancer stage.
OBJECTIVE:Helicobacter pylori (HP) is known to play an important role in the development of gastric cancer (GC). The aim of this study was to analyze the effect of HP eradication on the survival rate and cancer recurrence in patients who underwent subtotal gastrectomy for GC. DESIGN: Totally 1,031 patients diagnosed with gastric adenocarcinoma who received surgical treatment at the Seoul National University Bundang Hospital from 2003 to 2017 and positive for HP infection were analyzed. The overall and GC-related survival according to HP eradication were compared; risk factors for GC-specific death and cancer recurrence were analyzed, and propensity score matching (PSM) was performed. RESULTS: Statistically significant benefits of overall and GC-specific survival were observed in the eradicated group compared to the non-eradicated group (P < 0.001), and these benefits were maintained after PSM (P < 0.001) in both of early and advance stage. In Cox proportional hazards multivariate analyses, cancer stage (stage II, adjusted hazard ratio [aHR] = 9.33, P < 0.001; stage III or IV, aHR = 26.17, P < 0.001), and HP positivity (aHR = 3.41, P = 0.001) were independent risk factors for GC-specific death; cancer stage (cancer stage II, aHR = 7.08, P < 0.001; cancer stage III or IV, aHR = 19.64, P < 0.001) and HP positivity (aHR = 2.70; P = 0.005) were independent risk factors for cancer recurrence. CONCLUSION: Our results suggest that HP needed to be conducted more intensively in patients who are surgically treated for GC, regardless of cancer stage.
Authors: Ki Wook Kim; Nayoung Kim; Yonghoon Choi; Won Seok Kim; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Dong Ho Lee; Young Suk Park; Sang-Hoon Ahn; Do Joong Park; Hyung-Ho Kim; Hye Seung Lee; Ji-Won Kim; Jin Won Kim; Keun-Wook Lee; Won Chang; Ji Hoon Park; Yoon Jin Lee; Kyoung Ho Lee; Young Hoon Kim Journal: Gastric Cancer Date: 2021-02-18 Impact factor: 7.370
Authors: Yonghoon Choi; Nayoung Kim; Ki Wook Kim; Hyeong Ho Jo; Jaehyung Park; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Dong Ho Lee Journal: Ann Geriatr Med Res Date: 2022-03-18
Authors: Yonghoon Choi; Nayoung Kim; Ki Wook Kim; Hyeong Ho Jo; Jaehyung Park; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Dong Ho Lee; Hyeon Jeong Oh; Hye Seung Lee; Young Suk Park; Sang-Hoon Ahn; Yun-Suhk Suh; Do Joong Park; Hyung-Ho Kim; Ji-Won Kim; Jin Won Kim; Keun-Wook Lee; Won Chang; Ji Hoon Park; Yoon Jin Lee; Kyoung Ho Lee; Young Hoon Kim Journal: World J Gastroenterol Date: 2022-03-07 Impact factor: 5.742
Authors: Yonghoon Choi; Nayoung Kim; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Dong Ho Lee; Young Suk Park; Sang-Hoon Ahn; Yun-Suhk Suh; Do Joong Park; Hyung Ho Kim Journal: Gut Liver Date: 2022-05-15 Impact factor: 4.519